Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
elafin CRISPR Activation Plasmid (h): sc-401832-ACT
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- elafin CRISPR Activation Plasmid (h) is a synergistic activation mediator (SAM) transcription activation system designed to specifically upregulate gene expression
- elafin CRISPR Activation Plasmid (h) consists of three plasmids at a 1:1:1 mass ratio: a plasmid encoding the deactivated Cas9 (dCas9) nuclease (D10A and N863A) fused to the transactivation domain VP64, and a blasticidin resistance gene; a plasmid encoding the MS2-p65-HSF1 fusion protein, and a hygromycin resistance gene; a plasmid encoding a target-specific 20 nt guide RNA fused to two MS2 RNA aptamers, and a puromycin resistance gene
- The resulting SAM complex binds to a site-specific region approximately 200-250 nt upstream of the transcriptional start site and provides robust recruitment of transcription factors for highly efficient gene activation
- gRNAs encoded by elafin CRISPR Activation Plasmid (h) and elafin CRISPR Activation Plasmid (h2) target distinct regulatory regions upstream of the PI3 transcriptional start site. One or both designs may be available
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: elafin Antibody (H-2): sc-398075
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
elafin CRISPR Activation Plasmid (h) | sc-401832-ACT | 20 µg | $397.00 |
PI3 encodes elafin, a secreted serine protease inhibitor (also known as peptidase inhibitor 3) that restrains neutrophil elastase and related proteases to preserve epithelial barrier integrity during inflammation. Elafin participates in mucosal innate immunity and tissue remodeling by limiting protease-driven extracellular matrix degradation and modulating cytokine-rich microenvironments. Its expression is dynamically regulated in response to inflammatory cues in airway, skin, and gastrointestinal epithelia, linking PI3 to processes such as wound repair and host defense. Dysregulated PI3/elafin levels have been associated with chronic inflammatory conditions and protease–antiprotease imbalance observed in multiple epithelial disease contexts, supporting its use as a mechanistic marker in immunology and barrier biology research.
elafin CRISPR Activation Plasmid (h) provides a targeted, non-destructive approach to upregulating endogenous PI3 expression without altering the underlying DNA sequence.
elafin CRISPR Activation Plasmid (h) is a three-plasmid synergistic activation mediator (SAM) system engineered for highly efficient, site-specific transcriptional upregulation of the PI3 locus in human cell lines. The system is built around a catalytically inactive Cas9 (dCas9) carrying two inactivating mutations (D10A and N863A) that eliminate nuclease activity while preserving DNA binding. This dCas9 is fused to VP64, a potent transcriptional activator, and is co-expressed with a blasticidin resistance gene for selection. The second plasmid encodes the MS2-p65-HSF1 fusion protein, a secondary activator complex that works in concert with dCas9-VP64, alongside a hygromycin resistance gene. The third plasmid encodes a target-specific 20 nt sgRNA fused to two MS2 RNA aptamers that recruit the MS2-p65-HSF1 complex to the activation site, accompanied by a puromycin resistance gene. The three plasmids are delivered at a 1:1:1 mass ratio for balanced expression of all system components.
Once assembled at the target locus, the SAM complex binds within approximately 200 bp upstream of the PI3 transcriptional start site, where VP64, p65, and HSF1 act in concert to recruit transcriptional machinery and drive upregulation of endogenous elafin expression. Unlike nuclease-active Cas9, dCas9 does not introduce double-strand breaks or modify the genomic sequence, preserving the native PI3 locus and enabling the study of elafin-dependent transcriptional responses at the endogenous locus, making it a valuable tool for functional studies, target gene identification, and the modeling of elafin pathway restoration in tumor cells with silenced or reduced PI3 expression.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.